Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Sionna Therapeutics (Nasdaq: SION) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 at 9:45 a.m. PT / 12:45 p.m. ET. The company is a clinical-stage biopharmaceutical focused on developing medicines to normalize CFTR function for cystic fibrosis.
A live webcast of the presentation will be available on the company’s Investors > Events page at https://investors.sionnatx.com/, and a replay will be posted after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SION gained 4.18%, reflecting a moderate positive market reaction. Argus tracked a trough of -7.7% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $69M to the company's valuation, bringing the market cap to $1.72B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SION is down 4.69% with peers MAZE, RAPP, LENZ, ORIC, and SYRE also negative today (e.g., RAPP -6.46%, SYRE -6.65%), but momentum scanners did not flag a coordinated sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 24 | Investor conferences | Neutral | +1.6% | Management participation in early December 2025 healthcare investor conferences. |
| Nov 05 | Earnings and pipeline | Positive | -1.6% | Q3 2025 results, strong cash position, and advancement of SION‑719 and SION‑451. |
| Nov 04 | Investor conferences | Neutral | -1.2% | Planned fireside chats at November 2025 healthcare conferences with webcast access. |
| Oct 24 | Clinical data update | Positive | -1.0% | Phase 1 and preclinical data on NBD1 stabilizers SION‑719 and SION‑451 in CF. |
| Oct 21 | Clinical trial start | Positive | +32.0% | Initiation of PreciSION CF Phase 2a trial adding SION‑719 to standard of care. |
Conference participation headlines have produced modest, mixed reactions, while major clinical trial initiations drew the strongest positive move. Some positive fundamental updates have seen near-term price divergence.
Over the past few months, Sionna reported several key milestones. On Oct 21, 2025, it initiated the PreciSION CF Phase 2a trial of SION‑719, which coincided with a 31.99% gain. Subsequent Phase 1 data and preclinical results in late October and an earnings/10‑Q update on Nov 5, 2025 highlighted strong cash of $325.0M and progress toward mid‑2026 readouts. Multiple November and December conference participation announcements followed, generally producing only modest price moves, similar in nature to today’s conference-focused news.
Market Pulse Summary
This announcement highlights Sionna’s participation at the 44th Annual J.P. Morgan Healthcare Conference on Jan 13, 2026, providing a platform to showcase its CFTR‑focused pipeline. Recent history includes initiation of the PreciSION CF Phase 2a trial and strong liquidity of $325.0M reported in Q3 2025. Investors tracking the story may focus on upcoming mid‑2026 clinical readouts and ongoing regulatory filings and insider activity as key future reference points.
Key Terms
cystic fibrosis medical
cystic fibrosis transmembrane conductance regulator (cftr) protein medical
AI-generated analysis. Not financial advice.
WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13th, 2026 at 9:45 a.m. PT/12:45 p.m. ET.
A live webcast of the presentation will be available under the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. A replay will also be available following the event.
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Media Contact
Adam Daley
CG Life
212.253.8881
adaley@cglife.com
Investor Contact
Juliet Labadorf
ir@sionnatx.com
FAQ
When will Sionna Therapeutics (SION) present at the J.P. Morgan Healthcare Conference?
Where can investors watch the Sionna Therapeutics (SION) presentation on January 13, 2026?
Will a replay of the Sionna (SION) J.P. Morgan presentation be available after the event?
What is Sionna Therapeutics’ (SION) development focus mentioned for the January 13, 2026 presentation?
What time should East Coast investors tune in for the Sionna (SION) presentation on January 13, 2026?
